363 related articles for article (PubMed ID: 21240271)
21. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.
Umezu-Goto M; Kishi Y; Taira A; Hama K; Dohmae N; Takio K; Yamori T; Mills GB; Inoue K; Aoki J; Arai H
J Cell Biol; 2002 Jul; 158(2):227-33. PubMed ID: 12119361
[TBL] [Abstract][Full Text] [Related]
22. An essential oligomannosidic glycan chain in the catalytic domain of autotaxin, a secreted lysophospholipase-D.
Jansen S; Callewaert N; Dewerte I; Andries M; Ceulemans H; Bollen M
J Biol Chem; 2007 Apr; 282(15):11084-91. PubMed ID: 17307740
[TBL] [Abstract][Full Text] [Related]
23. Crystallization and preliminary X-ray crystallographic analysis of human autotaxin.
Inoue K; Tanaka N; Haga A; Yamasaki K; Umeda T; Kusakabe Y; Sakamoto Y; Nonaka T; Deyashiki Y; Nakamura KT
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Apr; 67(Pt 4):450-3. PubMed ID: 21505238
[TBL] [Abstract][Full Text] [Related]
24. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity.
Ferguson CG; Bigman CS; Richardson RD; van Meeteren LA; Moolenaar WH; Prestwich GD
Org Lett; 2006 May; 8(10):2023-6. PubMed ID: 16671772
[TBL] [Abstract][Full Text] [Related]
25. Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.
Fells JI; Lee SC; Fujiwara Y; Norman DD; Lim KG; Tsukahara R; Liu J; Patil R; Miller DD; Kirby RJ; Nelson S; Seibel W; Papoian R; Parrill AL; Baker DL; Bittman R; Tigyi G
Mol Pharmacol; 2013 Sep; 84(3):415-24. PubMed ID: 23793291
[TBL] [Abstract][Full Text] [Related]
26. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity.
Ferry G; Tellier E; Try A; Grés S; Naime I; Simon MF; Rodriguez M; Boucher J; Tack I; Gesta S; Chomarat P; Dieu M; Raes M; Galizzi JP; Valet P; Boutin JA; Saulnier-Blache JS
J Biol Chem; 2003 May; 278(20):18162-9. PubMed ID: 12642576
[TBL] [Abstract][Full Text] [Related]
27. Development of an activity-based probe for autotaxin.
Cavalli S; Houben AJ; Albers HM; van Tilburg EW; de Ru A; Aoki J; van Veelen P; Moolenaar WH; Ovaa H
Chembiochem; 2010 Nov; 11(16):2311-7. PubMed ID: 20941725
[TBL] [Abstract][Full Text] [Related]
28. Autotaxin--an LPA producing enzyme with diverse functions.
Nakanaga K; Hama K; Aoki J
J Biochem; 2010 Jul; 148(1):13-24. PubMed ID: 20495010
[TBL] [Abstract][Full Text] [Related]
29. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
30. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
31. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
[TBL] [Abstract][Full Text] [Related]
32. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.
Tanaka M; Okudaira S; Kishi Y; Ohkawa R; Iseki S; Ota M; Noji S; Yatomi Y; Aoki J; Arai H
J Biol Chem; 2006 Sep; 281(35):25822-30. PubMed ID: 16829511
[TBL] [Abstract][Full Text] [Related]
33. Structure-based design of novel boronic acid-based inhibitors of autotaxin.
Albers HM; Hendrickx LJ; van Tol RJ; Hausmann J; Perrakis A; Ovaa H
J Med Chem; 2011 Jul; 54(13):4619-26. PubMed ID: 21615078
[TBL] [Abstract][Full Text] [Related]
34. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate.
Song J; Clair T; Noh JH; Eun JW; Ryu SY; Lee SN; Ahn YM; Kim SY; Lee SH; Park WS; Yoo NJ; Lee JY; Nam SW
Biochem Biophys Res Commun; 2005 Nov; 337(3):967-75. PubMed ID: 16219296
[TBL] [Abstract][Full Text] [Related]
35. The Expression Regulation and Biological Function of Autotaxin.
Zhang X; Li M; Yin N; Zhang J
Cells; 2021 Apr; 10(4):. PubMed ID: 33921676
[TBL] [Abstract][Full Text] [Related]
36. Identification of Potent
Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
[TBL] [Abstract][Full Text] [Related]
37. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
Li S; Wang B; Xu Y; Zhang J
Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
[TBL] [Abstract][Full Text] [Related]
38. Regulation and biological activities of the autotaxin-LPA axis.
van Meeteren LA; Moolenaar WH
Prog Lipid Res; 2007 Mar; 46(2):145-60. PubMed ID: 17459484
[TBL] [Abstract][Full Text] [Related]
39. Discovery of potent inhibitors of the lysophospholipase autotaxin.
Shah P; Cheasty A; Foxton C; Raynham T; Farooq M; Gutierrez IF; Lejeune A; Pritchard M; Turnbull A; Pang L; Owen P; Boyd S; Stowell A; Jordan A; Hamilton NM; Hitchin JR; Stockley M; MacDonald E; Quesada MJ; Trivier E; Skeete J; Ovaa H; Moolenaar WH; Ryder H
Bioorg Med Chem Lett; 2016 Nov; 26(22):5403-5410. PubMed ID: 27780639
[TBL] [Abstract][Full Text] [Related]
40. Novel point mutations attenuate autotaxin activity.
Koh E; Bandle RW; Roberts DD; Stracke ML; Clair T
Lipids Health Dis; 2009 Feb; 8():4. PubMed ID: 19222837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]